|
|
Article: Chiron Reports 2005 Adjusted Earnings of $1.34 Per Share, GAAP Earnings of $0.97 Per Share; FLUVIRIN(R) Influenza Virus Vaccine Sales Drive 12 Percent Product Sales Growth Compared to 2004.
- Article from:
- Business Wire
- Article date:
- January 31, 2006
CopyrightCOPYRIGHT 2006 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
EMERYVILLE, Calif. -- Chiron Corporation (NASDAQ: CHIR) today reported financial results for the year ended December 31, 2005.
OVERVIEW
--Chiron's FLUVIRIN(R) influenza virus vaccine returned to the U.S. market in 2005. The company sold approximately 13 million doses of the vaccine to its customers in 2005.
--Total revenues for the year ended December 31, 2005, increased 11 percent compared to the year ended December 31, 2004.
--Chiron continues to build on the company's promising pandemic influenza vaccine program. The company announced preliminary data from a clinical study of an investigational vaccine candidate, both with and ...
Related newspaper, magazine, and journal articles:
|